BBOT Reports Strong 2025 Results, Sets Stage for 2026 Clinical Readouts
Event summary
- BBOT reported $425.5M in cash as of December 31, 2025, with runway into 2028.
- BBO-8520 showed 65% ORR in KRASG12C NSCLC monotherapy with differentiated safety profile.
- BBO-11818 achieved first confirmed partial response in PDAC as monotherapy.
- BBO-10203 demonstrated no hyperglycemia without HbA1c restrictions in clinical trials.
- 2025 R&D expenses rose to $121.2M from $73.1M in 2024 due to clinical trial and manufacturing costs.
The big picture
BBOT's 2025 results highlight its strategic focus on RAS-pathway malignancies, positioning it as a key player in oncology. The company's differentiated portfolio and upcoming clinical readouts in 2026 could set new standards for KRAS-driven tumor treatments. With a strong cash position and multiple data catalysts on the horizon, BBOT is poised to capitalize on the growing demand for targeted cancer therapies.
What we're watching
- Combination Viability
- How BBOT's internal combination strategies with BBO-8520, BBO-11818, and BBO-10203 will perform in clinical trials.
- Regulatory Progress
- Whether the FDA's Fast Track designation for BBO-8520 will accelerate approval timelines.
- Financial Discipline
- The pace at which BBOT will manage its cash runway to support operations through 2028.
Related topics